Crestolip

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Crestolip

Quick Facts

Property Description
Active ingredient Rosuvastatin calcium (INN)
Form Film-coated tablet (Oral, Rx-only)
Pharmacological class HMG-CoA Reductase Inhibitors (Statins)
General purpose Management of dyslipidaemia / Modification of lipid profiles
Origin Synthetic lipid-lowering agent

What Kind of Medicine is Crestolip?

Crestolip is a registered trade name for a prescription medication containing the active substance Rosuvastatin calcium. It is classified under the HMG-CoA Reductase Inhibitors (or Statins) pharmacological class, a category of agents used to manage blood lipids. Rosuvastatin is confirmed to be a potent synthetic lipid-lowering agent distinguishing it from drugs with natural or semi-synthetic origins. This classification identifies the drug as a direct, chemically manufactured intervention targeting the body’s endogenous production of cholesterol.

Composition, Form, and General Purpose

This medication is prepared as a single-ingredient product, typically supplied as an oral film-coated tablet. The composition features Rosuvastatin calcium and necessary solid excipients, without other active therapeutic agents. Its focused composition is intended to provide the full benefit of its unique properties. The essential therapeutic purpose of the Rosuvastatin compound is the rigorous management of blood lipid abnormalities, known as dyslipidaemia. It is utilized to effectively reduce the concentration of low-density lipoprotein cholesterol (LDL Cholesterol) and other detrimental lipids, including triglycerides. By achieving this necessary modification of the lipid profile, the medicine is intended to provide robust support for individuals managing the elevated levels of these fat-like substances.

Regulatory References

  1. NIH DailyMed for Rosuvastatin
  2. Rosuvastatin MedlinePlus Drug Information

What side effects are possible with Crestolip?

Possible Side Effects and Safety Information

Official regulatory documents categorize the safety profile of Crestolip (rosuvastatin) by key adverse reactions, serious risks, and specific population restrictions.


Serious and Clinically Significant Adverse Reactions

The most serious safety concerns documented in regulatory labeling relate to skeletal muscle and hepatic effects, which require careful monitoring. These include:

  • Skeletal Muscle Damage (Myopathy and Rhabdomyolysis): This can occur at any dose but the risk is documented to be higher at the maximum 40 mg dose. Rhabdomyolysis is a rare, severe muscle breakdown that can lead to acute renal (kidney) failure. Immune-Mediated Necrotizing Myopathy (IMNM), a rare autoimmune muscle disease, has also been reported in association with statin use.
  • Hepatic Dysfunction: Persistent increases in serum transaminase liver enzymes have occurred. Rare postmarketing reports of fatal and non-fatal hepatic failure are documented. Liver enzyme testing is advised before initiating therapy and as clinically indicated if symptoms of liver injury occur.
  • Metabolic Effects: Increases in HbA1c and fasting serum glucose levels have been reported, and the drug may increase the risk of developing diabetes mellitus in at-risk individuals.

Common Adverse Reactions

Adverse reactions reported in clinical trials, with an incidence rate typically greater than or equal to 2%, include:

  • Headache
  • Nausea
  • Myalgia (muscle pain)
  • Asthenia (weakness)
  • Constipation
  • Abdominal pain

Safety Restrictions and Contraindications

Crestolip is contraindicated and should not be used in the following circumstances, as documented by regulatory bodies:

  • In patients with active liver disease or unexplained persistent elevations of hepatic transaminases.
  • During pregnancy or while breastfeeding, as the drug may cause fetal harm and is not recommended during lactation.
  • With concomitant use of certain medications, such as cyclosporine, due to a significantly increased risk of myopathy and rhabdomyolysis.

Specific precautions are noted for patients of Asian descent, those with renal impairment, and those ge 65 years of age, as these factors may increase the risk of skeletal muscle effects.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory information for rosuvastatin calcium, the active substance in Crestolip, provides specific guidance on overdose management. This guidance is primarily focused on the lack of a specific intervention and the actions required to secure immediate medical attention.

Official Overdose Profile

Feature Regulatory Documentation Statement
Documented Manifestations No specific signs, symptoms, or laboratory abnormalities resulting from an overdose are formally documented in the official Overdosage section.
Antidote Availability No specific antidote for rosuvastatin overdose is known.

Immediate Actions and Management

In the event of a suspected or actual overdose, it is mandated to seek immediate medical attention. Official regulatory guidance directs individuals to contact the Poison Help Line or a medical toxicologist for additional, specific management recommendations.

Treatment must be strictly symptomatic and supportive measures should be instituted as required based on the patient's clinical presentation. A key procedural constraint noted in regulatory labeling is that advanced interventions such as haemodialysis do not significantly enhance the clearance of the active substance from the body.

Connection to the Overall Overdose Profile

The regulatory profile is structured by the explicit absence of documented unique overdose symptoms and the lack of a known antidote. This establishes that the required emergency action is to secure expert guidance immediately and focus entirely on symptomatic and supportive care.

Therapeutic Uses of Crestolip

What Crestolip Treats: Main Uses and Benefits

The primary role of Crestolip may be part of a long-term strategy that assists in reducing the risk of major disease events, that is applied in addressing systemic imbalance of lipids. The medication is commonly used for both lipid modification and the reduction of cardiovascular risk.

The medication is generally applied across conditions involving episodic or fluctuating manifestations of lipids, including primary hypercholesterolemia, combined (mixed) dyslipidemia, and severe, inherited forms like familial hypercholesterolemia (HeFH/HoFH). The therapeutic benefit may contribute to a noticeable modification of the lipid profile, which supports the management of chronic vascular disease.

The core benefit is protective, as the medication assists in reducing the probability of future heart attacks and strokes. This is relevant in both the primary prevention setting and the secondary prevention setting.

“The primary goal of this therapy is to address the underlying asymptomatic risk factors associated with elevated cholesterol and triglycerides.”

Property Description
Quick Fact: Therapeutic Benefit
Core Therapeutic Goal Assists with managing high LDL-C and triglycerides
Common Scenario Long-term management of high cardiovascular risk
Main Patient Benefit Contributes to easing the overall symptom load related to cardiovascular risk
Primary Use Context Used alongside diet and other non-pharmacological methods

Regulatory References

  1. NIH DailyMed Rosuvastatin Label

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Crestolip (Rosuvastatin)

The population eligibility for Crestolip is strictly defined by regulatory documents based on age, organ function, and physiological state.

Eligibility Classification Status and Population
Contraindicated Women who are pregnant or breastfeeding; patients with active liver disease or unexplained persistent transaminase elevations greater than 3 imes ULN; and individuals with known hypersensitivity to rosuvastatin.
Age-Related Eligibility Approved for use in adults and certain pediatric patients (starting from age 7 or 8 years for specific inherited cholesterol disorders). Use is not recommended in children younger than 6 years.
Restricted Use Patients with severe renal impairment (creatinine clearance < 30 mL/ min) are contraindicated in some regions, or restricted to a maximum dose of 10 mg once daily in others. A lower starting dose may be necessary for patients over 70 years of age and for those of Asian descent.
Comorbidity Constraints The highest 40 mg dose is generally contraindicated in patients with risk factors for myopathy, which include untreated hypothyroidism, genetic muscle disorders, and substantial alcohol abuse.

Official regulatory documents define who can and cannot use the medicine by establishing clear prohibitions and conditions for use, ensuring the product is prescribed only when the labeled criteria are met.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Crestolip (rosuvastatin) is defined by pharmacokinetic mechanisms that significantly increase the drug’s systemic exposure, often linked to inhibition of the OATP1B1 and BCRP drug transporters, or by additive pharmacodynamic risk with other substances. This structure establishes formal constraints on co-administration according to official regulatory documents.

Interaction Type Interacting Substances (Examples) Official Regulatory Constraint
Contraindicated Co-administration Cyclosporine, Select Antiviral Combinations Concomitant use is formally prohibited or not recommended due to significant pharmacokinetic interference.
Exposure Modification (Increase) Gemfibrozil, Protease Inhibitors (e.g., Lopinavir/Ritonavir), Kinase Inhibitors Strict maximum dose restrictions for rosuvastatin are required to mitigate the documented increase in systemic exposure.
Absorption Timing Rule Aluminum and Magnesium Hydroxide Combination Antacids Crestolip must be administered at least 2 hours before the antacid to prevent reduced plasma concentrations.
Additive Pharmacodynamic Risk Other Fibrates, high-dose Niacin, Colchicine, Red Yeast Rice An officially documented additive risk of skeletal muscle effects (myopathy, rhabdomyolysis) exists with these agents.

The regulatory framework establishes mandatory dose limitations or prohibitions when Crestolip is co-administered with select transporter-inhibiting agents. Furthermore, the 40 mg dose is formally contraindicated in individuals with severe renal impairment due to the risk of accumulation and increased exposure. Asian patients are also noted in the official labeling as having documented two-fold higher systemic exposure, requiring specific starting dose considerations. The overall interaction structure emphasizes managing exposure and additive muscle toxicity risk.

Mechanism of Action

Inhibiting the Core Synthesis Pathway

The mechanism of action begins in the liver where Rosuvastatin acts as a competitive inhibitor of HMG-CoA Reductase (HMGCR), the enzyme responsible for initiating the body's cholesterol production pathway. This targeted inhibition effectively restricts the supply of internally synthesized cholesterol, initiating a necessary biochemical signal within the liver cells.

Enhancing LDL Receptor Clearance

The resulting drop in internal cholesterol levels activates a compensatory homeostatic mechanism that involves the upregulation of LDL Receptors on the hepatocyte surface. The increase in these receptors significantly enhances the liver's capacity to scavenge and remove Low-Density Lipoprotein Cholesterol (LDL-C) particles directly from the bloodstream, resulting in a reduction in plasma LDL-C levels.

Pleiotropic Vascular Modulation

Independent of lipid reduction, the drug engages secondary, pleiotropic mechanisms that influence the systemic environment. These actions include modulating inflammatory responses by reducing markers like C-Reactive Protein (CRP) and influencing the function of the vascular endothelium. These effects contribute to the drug's overall profile by modulating dysregulated inflammatory signaling pathways.

Dosage and Administration Information

How Crestolip is Used: Official Administration Guidelines

Crestolip, which contains Rosuvastatin calcium, is administered exclusively by the oral route as a film-coated tablet, available in labeled strengths of 5 mg, 10 mg, 20 mg, and 40 mg. The official dosing regimen requires the medicine to be taken once daily as a single dose. Administration is permitted at any time of day, and the tablet may be swallowed with or without food. For proper use, the tablet must be swallowed whole and not crushed or chewed.

The standard starting doses for adults are typically 10 mg or 20 mg once daily. Dose titration is a gradual process; adjustments to the dose amount, if required, should be implemented at intervals of 4 weeks or more, as dictated by the patient's lipid profile response. The maximum recommended daily dose is 40 mg, a dose that is officially reserved for individuals who have not achieved their treatment goals on the 20 mg dose.

Population-specific guidelines exist for proper use. For instance, in cases of severe renal impairment (non-dialysis dependent), the starting dose must be 5 mg, and the dose should not exceed 10 mg once daily. Due to observed increases in systemic exposure, guidelines advise considering a 5 mg starting dose for patients of Asian ancestry. If a dose is missed, patients are instructed to skip the missed dose and continue with the next scheduled administration; doubling the dose is prohibited.

Recent Clinical Evidence

Research evidence / Overview of studies for Crestolip

Evidence for Use in Lipid Profile Modification (Dyslipidaemia Management)

Research has primarily examined the levels of fat-like substances, or lipid biomarkers, in the blood. Studies for this purpose were largely conducted as randomized controlled trials (RCTs) over short-to-intermediate time intervals, typically lasting a few weeks to a few months. The primary focus of this research was to monitor changes in lipid markers, specifically LDL-C, Total Cholesterol, Triglycerides, and HDL-C. The populations observed in these studies included adults with primary high cholesterol and mixed dyslipidemia, as well as individuals managing inherited forms of the condition.

Findings indicate patterns where measured changes in lipid profiles were recorded during the observation period. Comparative evidence against all available similar medicines for these specific outcomes is lacking due to the variety of doses and study design types, making cross-trial interpretation complex.

Evidence for Use in Cardiovascular Risk Reduction

Research also explored whether the medication may be associated with patterns in the occurrence of a first major cardiovascular event, such as a nonfatal heart attack or stroke. These large-scale studies were conducted as randomized controlled trials (RCTs) that included a placebo comparison and extended over several years. The main outcomes describing episodic or acute changes that were monitored included the composite major adverse cardiovascular event (MACE) endpoint and all-cause mortality.

Long-term, placebo-controlled trials research describes the incidence rate of the composite MACE endpoint and the incidence of all-cause mortality in the treatment group versus the placebo group. A key limitation is that comparative evidence is lacking from a single, definitive, long-term RCT directly comparing event rates against all other statin agents across all doses and populations.

Evidence in Specific Patient Populations

Research was studied for specific populations in addition to the broad adult cohort. This includes children and adolescents (age 7 and older) with inherited high cholesterol, such as familial hypercholesterolemia. Subgroup analyses from major trials also examined the data in older adults, including those aged 70 and above. Data for certain groups remain insufficient when attempting to generalize findings, and the sample sizes were modest in the dedicated trials for the pediatric population.

Frequently Asked Questions (FAQ)

Common questions about Crestolip (FAQ)


Q: Is Crestolip safe to take with common pain relievers like ibuprofen?

A: Official drug product information does not commonly list specific warnings or formal restrictions against taking Crestolip alongside non-prescription pain relievers such as ibuprofen. The official drug labels, which outline drug-drug interactions, primarily focus on agents that significantly increase the concentration of Crestolip in the body.


Q: Are there any specific supplements that interact with Crestolip?

A: Regulatory documents indicate that co-administration with certain products carries an increased risk of serious muscle-related issues. This additive risk is documented with supplements like niacin (Vitamin B3) and products containing substances similar to statins, such as Red Yeast Rice. Official information specifies certain supplements must be disclosed to healthcare providers.


Q: Are there different strengths of Crestolip tablets available?

A: Yes, Crestolip tablets are supplied in various labeled strengths, which are 5 mg, 10 mg, 20 mg, and 40 mg. These different strengths allow a healthcare provider to adjust the dose based on the necessary lipid level goals.


Q: What is the primary evidence or research supporting Crestolip's use?

A: Research reviewed by regulatory bodies supports the drug's use in two primary areas: first, as an aid to diet in reducing LDL-C and other unhealthy lipids; and second, to reduce the risk of major cardiovascular events, such as heart attack and stroke, in adults who are identified as being at high risk.


Q: Are there differences between the Crestolip brand and its generic equivalents?

A: Generic versions of Crestolip contain the same active ingredient (Rosuvastatin) and are required by regulatory agencies to be equally effective and safe as the brand name drug in the same strength. The main differences are typically found in the inactive ingredients used, the tablet's appearance, or the cost.


Q: How quickly should I expect to see an effect from Crestolip?

A: According to official product information, the effect of Crestolip on reducing cholesterol levels is often assessed relatively quickly. Healthcare providers typically assess your LDL-C (cholesterol) response as early as 4 weeks after starting the medicine or after a dose change.


Q: What happens if I stop taking Crestolip suddenly?

A: Official information advises against suddenly stopping the medication unless directed by a healthcare provider. The effects of the medicine are monitored through lab tests, not by physical symptoms, and stopping could lead to the return of unhealthy lipid levels.


Q: Is there a risk of memory loss while taking Crestolip?

A: The official labels acknowledge there have been rare post-marketing reports of cognitive impairment, which can include issues like memory loss or forgetfulness, associated with statin use. These effects are generally described as non-serious and are typically reported to be reversible when the medicine is stopped.


Q: Does taking Crestolip affect my blood sugar levels?

A: Regulatory warnings indicate that use of the drug has been associated with increases in HbA1c (a measure of average blood sugar) and fasting glucose levels. The medicine may also increase the risk of developing diabetes mellitus in individuals who have pre-existing risk factors.


Q: Does food change how Crestolip is absorbed?

A: The official administration guidelines state that Crestolip is approved to be taken as a single daily dose with or without food. This indicates that consuming the medication alongside a meal does not significantly change the way the drug is absorbed by the body.


Q: Can older adults safely take Crestolip?

A: Official documents note that advanced age (defined as ge 65 years) is one of the factors that can increase the risk of skeletal muscle effects. For this reason, certain specific patient groups, such as those over 70 years of age or with renal impairment, may require a lower starting dose as a precaution.


Q: Is it common to feel tired when first starting Crestolip?

A: Official lists of common side effects in clinical trials include asthenia, which is a medical term for weakness or lack of energy. This reaction was reported with an incidence rate of ge 2% in studies, indicating it is one of the more frequently observed effects when starting the medicine.


Q: Is the purpose of Crestolip mainly preventative?

A: One of the approved indications listed in regulatory documents is explicitly to reduce the risk of serious cardiovascular events like stroke or heart attack in individuals who are considered to be at high risk. The other main purpose is therapeutic management of unhealthy lipid levels.


Q: Why is consistent use important for Crestolip?

A: The medicine is described as working best when a constant amount of the active ingredient remains in the blood. Consistent administration is necessary to maintain the desired effect on lipid levels, according to official guidance.


Q: What are common user experiences reported when starting Crestolip?

A: The most frequently reported adverse reactions from clinical trials include common, mild issues such as headache, nausea, constipation, abdominal pain, and muscle pain (myalgia). These are the effects users are most likely to observe when beginning therapy.


Q: Can Crestolip cause dizziness or affect driving?

A: Official adverse reaction lists include the possibility of dizziness. Individuals are advised that if they feel dizzy or weak, they should not drive or operate machinery until they feel well enough to safely do so.


Q: Can Crestolip cause skin reactions?

A: While not listed as a common side effect, official drug information documents mention that serious reactions, such as rash or hives, have been reported. Any new or serious skin reactions should be brought to the attention of a healthcare provider.


Q: Is Crestolip typically taken in the morning or evening?

A: The official guidance specifies that the medicine can be taken as a single dose at any time of day—morning, afternoon, or evening. The key instruction is to maintain consistent daily administration, rather than focusing on a specific time.

How should Crestolip be stored and disposed of?

How to Store and Dispose of Crestolip (Rosuvastatin Calcium)

Crestolip tablets must be stored at a controlled room temperature, maintaining a range between 15°C and 30°C (59°F and 86°F). The medication must be protected from moisture and light to maintain its stability.

Storage Requirements

  • Container Integrity: Keep the medicine in its original container and ensure the container is tightly closed.
  • Child Safety: It is a mandatory requirement to store the tablets out of the sight and reach of children.

Disposal

Disposal of unused or expired Crestolip must follow official local regulations. Rosuvastatin is not on the FDA's flush list. For disposal in household trash, tablets should be mixed with an undesirable substance, such as coffee grounds, and placed in a sealed bag before discarding, ensuring the medication does not enter the wastewater system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Crestolip found in:

A-Z Index: